

### STATEMENT BY APPLICANT

2008 Use (as many sheets as necessary)

Sheet

1

of

2

**Application Number**

10/531.495

**Filing Date**

April 15, 2005

**First Named Inventor****Michael J. Breslin**

### Group Art Unit

**To be determined**

**Examiner Name**

**To be determined**

Attorney Docket Number

21231 YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		PCT	WO 03/105855		Merck & Co., Inc.	12/24/2003
		PCT	WO 93/20099		Yamanouchi Pharm. Co., Ltd.	10/14/1993
		PCT	WO 2005/019206		Merck & Co., Inc.	03/03/2005
		PCT	WO 2005/019205		Merck & Co., Inc.	03/03/2005
		PCT	WO 03/100417		Merck & Co., Inc.	12/24/2003
		EPO	EP 418,845		Fujisawa Pharm. Co., Ltd.	06/30/2005

Not provided

**Examiner  
Signature**

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Marck & Co., Inc., 7/11/2005

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/531,495	
			Filing Date	April 15, 2005	
			First Named Inventor	Michael J. Breslin	
			Group Art Unit	To be determined	
			Examiner Name	To be determined	
Sheet	2	of	2	Attorney Docket Number	21231 YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
YC		M. J. Breslin, et al., Database CALPUS on STN, DN:139:307756 (2003)
		M. Bujard, et al., Tetrahedron Letters (40), pgs. 8785 - 8788 (1999)
		M.J.S. Carpes, et al., Synlett., No. 7, pgs. 1037 - 1039 (2000)
		C. Sonesson, et al., J. Org. Chem. 1996, Vol. 61, pg. 4756-4763
		N. Iwasawa, et al., J. Org. Chem. 1998, Vol. 63, pg. 3164-3165
↓		N. Iwasawa, et al., J. Org. Chem. 1997, Vol. 62, pg. 1918-1919
YC		R. Mison, et al., J. Chem. Research(S), 1989, 126-127
		<del>O. Ycbdri, et al., Bulletin De La Societe Chimique de France, 1983, pg. 195-201</del> <i>No translation</i>
		<del>A. Ranjon, Bulletin De La Societe Chimique de France, 1971, pg. 2068-2072</del> <i>Not provided</i>
YC		A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621
↓		N. Moss, et al., J. Med. Chem., Vol 36 (20) pgs. 3005-3009 (1993)
		M. Fraley, et al., "Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters (2006)
YC		R. Garbaccio, et al., "Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorganic & Medicinal Chemistry Letters (2006)

Examiner Signature	/Yong Chu/	Date Considered	07/13/2006
--------------------	------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005